focu
articl
review
recent
advanc
proteom
analysi
human
bodi
fluid
includ
plasmaserum
urin
cerebrospin
fluid
saliva
bronchoalveolar
lavag
fluid
synovi
fluid
nippl
aspir
fluid
tear
fluid
amniot
fluid
well
applic
human
diseas
biomark
discoveri
aim
summar
proteom
technolog
current
use
global
identif
quantif
bodi
fluid
protein
elabor
put
biomark
discov
varieti
human
diseas
human
bodi
fluid
proteom
hbfp
analysi
critic
concern
perspect
emerg
field
also
discuss
advanc
made
proteom
technolog
impact
hbfp
analysi
search
clinic
relev
diseas
biomark
would
realiz
futur
proteom
wide
envis
power
mean
biomed
research
signific
advanc
ms
proteom
technolog
protein
biomark
discoveri
becom
one
central
applic
proteom
one
might
think
tissu
biopsi
ideal
specimen
diseas
biomark
studi
howev
term
diseas
diagnosi
prognosi
human
bodi
fluid
eg
blood
urin
saliva
appear
attract
bodi
fluid
test
provid
sever
key
advantag
includ
low
invas
minimum
cost
easi
sampl
collect
process
analysi
human
bodi
fluid
proteom
hbfp
becom
one
promis
approach
discoveri
biomark
human
diseas
hbfp
analysi
inher
challeng
bodi
fluid
contain
larg
number
protein
could
modifi
varieti
form
due
complex
hbfp
number
variabl
need
consid
includ
sampl
prepar
handl
protein
prefraction
affin
deplet
highli
abund
protein
isol
subproteom
eg
glycoproteom
phosphoproteom
multidimension
chromatograph
separ
quantif
protein
data
analysi
databas
search
criteria
etc
understand
natur
inher
limit
necessari
step
illustr
best
approach
tool
analysi
specif
bodi
fluid
proteom
discoveri
correspond
diseas
biomark
articl
review
progress
hbfp
analysi
applic
bodi
fluid
biomark
discoveri
human
diseas
special
featur
challeng
perspect
regard
bodi
fluid
proteom
also
discuss
know
current
statu
critic
concern
hbfp
analysi
help
advanc
futur
investig
emerg
field
human
plasma
protein
origin
varieti
tissu
blood
cell
result
secret
leakag
numer
biomed
studi
demonstr
plasma
protein
level
reflect
human
physiolog
patholog
state
use
diseas
diagnosi
prognosi
sampl
prepar
handl
critic
plasmaserum
proteom
analysi
plasma
sampl
obtain
blood
withdrawn
presenc
anticoagul
edta
sodium
citrat
heparin
centrifug
remov
blood
cell
howev
absenc
anticoagul
serum
sampl
obtain
blood
clot
cellular
element
centrifug
remov
serum
protein
composit
larg
differ
plasma
standard
sampl
handl
prepar
whether
use
plasma
serum
proteom
analysi
question
remain
answer
second
critic
issu
complex
proteom
plasmaserum
contain
huge
number
protein
differ
extraordinari
dynam
rang
least
order
magnitud
mani
protein
glycosyl
bound
carrier
protein
global
quantifi
protein
free
bound
modifi
form
remain
critic
challeng
littl
effort
invest
standard
sampl
prepar
handl
procedur
plasmaserum
proteom
analysi
presum
wide
rang
preanalyt
variabl
also
mani
technolog
platform
current
use
plasmaserum
proteom
analysi
thu
practic
defin
singl
list
standard
sampl
prepar
handl
procedur
proteom
platform
howev
realiti
extrem
import
biomark
develop
process
consid
candid
biomark
need
repeatedli
valid
larg
independ
sampl
cohort
usual
format
multicent
studi
sever
recent
studi
clearli
indic
sampl
handl
variabl
clot
condit
time
storag
temperatur
storag
time
storag
tube
freezethaw
cycl
proteas
inhibitor
signific
effect
result
plasmaserum
proteom
analysi
gener
sampl
aliquot
store
minim
thawrefreez
cycl
prefer
frozen
liquid
nitrogen
proteas
inhibitor
would
desir
inhibitor
cocktail
use
caution
peptid
inhibitor
eg
highconcentr
aprotinin
may
interfer
ms
analysi
sever
small
molecul
inhibitor
pmsf
aebsf
form
coval
bond
protein
process
whole
blood
coagul
cellular
element
especi
platelet
secret
varieti
compon
therefor
blood
cell
remov
immedi
provid
optim
analyt
stabil
investig
concern
platelet
contamin
option
includ
filtrat
plasma
membran
filter
doubl
centrifug
specimen
use
addit
minim
platelet
activ
mixtur
citrat
theophyllin
adenosin
dipyridamol
overal
sampl
collect
prepar
handl
procedur
consist
across
whole
studi
strongli
recommend
one
care
document
condit
sampl
prepar
handl
dilig
track
preanalyt
variabl
certifi
refer
materi
develop
sampl
qualiti
control
qualiti
assur
hupoplasma
proteom
project
ppp
specimen
committe
conclud
plasma
prefer
serum
due
less
degrad
ex
vivo
within
four
hupo
specimen
edta
plasma
citrat
plasma
heparin
plasma
serum
examin
plateletdeplet
citrat
plasma
superior
serum
peptidom
analysi
proteas
inhibitor
especi
aprotinin
recommend
interfer
analysi
peptid
howev
still
controversi
whether
serum
plasma
use
archiv
specimen
frequent
sera
plasmaserum
proteom
analysi
hamper
predomin
sever
highli
abund
protein
includ
albumin
immunoglobulin
ig
fibrinogen
haptoglobin
hg
isoform
fragment
deplet
highli
abund
protein
often
desir
prior
proteom
analysi
cibacron
blue
dye
method
tradit
way
deplet
albumin
howev
bind
albumin
cibacron
blue
dye
nonspecif
sensit
specif
effect
mabbas
immunoaffin
resin
column
remov
igg
realiz
protein
g
resin
column
compar
cibacron
blue
dye
protein
g
method
immunoaffin
deplet
use
multipl
affin
remov
column
marc
effect
simultan
remov
multipl
abund
protein
minim
carryov
high
longev
minim
nonspecif
bind
immunodeplet
effect
realiz
igi
antibodi
microbead
peptidebas
affin
medium
protein
precipit
tcaaceton
naclethanol
also
appear
use
deplet
albumin
concern
regard
whether
less
abund
serum
protein
remov
along
albumin
hg
commonli
deplet
protein
immunodeplet
method
remov
good
portion
highli
abund
protein
howev
problemat
column
may
also
remov
protein
eg
cytokin
nonspecif
bind
possibl
approach
address
problem
disrupt
bind
low
molecular
weight
lmw
protein
carrier
protein
albuminigg
instanc
partli
denatur
condit
ad
acn
may
disrupt
bind
lmw
albuminigg
result
increas
number
protein
detect
denatur
condit
compar
nativ
condit
presenc
acn
serum
provid
better
enrich
lmw
protein
compar
acn
condit
addit
rather
deplet
highli
abund
protein
would
promis
develop
method
function
nanoparticl
enrich
low
abund
proteinspeptid
reduc
protein
concentr
rang
varieti
proteom
platform
appli
global
identif
plasma
serum
protein
tabl
list
repres
proteom
analysi
plasmaserum
bodi
fluid
interpret
list
data
cautiou
consid
differ
criteria
algorithm
might
use
databas
search
assign
protein
id
simpl
shotgun
experi
base
lcmsm
typic
yield
list
hundr
distinct
protein
multiplex
proteom
platform
often
consist
prefraction
multidimension
separ
msm
techniqu
requir
order
achiev
comprehens
analysi
prefraction
plasmaserum
protein
realiz
use
number
separ
techniqu
includ
rplc
strong
cation
exchang
scx
chromatographi
sec
anionexchang
chromatographi
aec
anion
displac
liquid
chromatofocus
chromatographi
sdspage
slice
gel
band
membranebas
electrophoresi
gradiflow
fraction
free
flow
electrophoresi
ffe
liquidphas
ief
chromatofocusingrplc
multiplex
techniqu
eg
combin
sec
aec
solut
ief
sdspage
enhanc
resolv
power
order
conclud
separ
techniqu
effici
prefraction
plasmaserum
protein
hupoppp
studi
carri
compar
scx
slice
sdspage
gel
band
liquidphas
ief
prefraction
base
scx
result
largest
number
identifi
protein
follow
gel
slice
liquidphas
ief
import
observ
method
reveal
set
uniqu
protein
therefor
comprehens
identif
plasmaserum
protein
sever
differ
prefraction
method
use
parallel
liquidphas
ief
ampholytefre
appear
effect
prefraction
peptid
use
liquid
ief
prior
lcmsm
analysi
uniqu
peptid
identifi
correspond
serum
protein
total
protein
identifi
liquid
ief
fraction
fraction
scx
analyz
lcmsm
hupoppp
project
led
number
studi
standard
sampl
prepar
handl
evalu
proteom
technolog
analysi
subproteom
glycoproteom
peptidom
data
analysi
algorithm
manag
databas
develop
proteom
platform
test
includ
lcfticr
ms
antibodi
array
selditofm
tabl
import
observ
differ
platform
reveal
distinct
subset
protein
like
complementari
toward
identif
serum
protein
reevalu
three
publish
plasma
proteom
studi
also
indic
minimum
overlap
protein
identifi
differ
proteom
platform
protein
found
literatur
search
strongli
bias
toward
signal
sequencecontain
extracellular
protein
three
proteom
method
show
much
higher
represent
cellular
protein
includ
nuclear
cytoplasm
kinesin
complex
protein
result
hupoppp
pilot
phase
studi
yield
intern
protein
index
ipi
protein
identifi
one
peptid
protein
identifi
two
peptid
protein
identifi
protein
found
cardiovascularrel
function
manual
literatur
search
use
rigor
statist
approach
take
account
length
code
region
gene
multipl
hypothesistest
techniqu
reduc
set
protein
report
confid
level
least
plasmaserum
peptidom
refer
lmw
fraction
plasmaserum
proteom
high
molecular
weight
protein
remov
lmw
fraction
made
sever
class
physiolog
import
protein
cytokin
chemokin
peptid
hormon
well
proteolyt
fragment
larger
protein
peptidom
aim
analysi
peptidom
discoveri
lmw
biomark
human
diseas
suitabl
specimen
sampl
handl
procedur
crucial
peptidom
analysi
plasmaserum
peptidom
often
prepar
whole
proteom
use
physic
method
centrifug
ultrafiltr
gel
chromatographi
precipit
sampl
prepar
artifici
occur
process
eg
cell
lysi
proteolysi
minim
analysi
profil
plasmaserum
peptidom
perform
lcmsm
fticrm
malditofm
selditofm
lcm
magnet
beadsparticl
use
enrich
serum
peptid
greatli
enhanc
reproduc
malditofm
analysi
peptid
mani
lmw
compon
serumplasma
peptidom
bound
carrier
protein
examin
lmw
speci
bound
specif
carrier
protein
may
disclos
import
diagnost
inform
instanc
cancerrel
protein
lowabund
nuclear
protein
link
cancer
suscept
repres
sera
seri
specif
fragment
bound
albumin
demonstr
carrierprotein
harvest
provid
rich
sourc
candid
peptid
protein
potenti
divers
tissu
cellular
origin
may
reflect
import
diseaserel
inform
mani
protein
human
plasma
glycosyl
chang
extent
glycosyl
carbohydr
structur
protein
link
cancer
diseas
state
highlight
clinic
import
modif
indic
patholog
mechan
lectin
affin
chromatographi
lac
often
use
enrich
either
glycoprotein
glycopeptid
prior
ms
analysi
use
multilectin
affin
column
maxim
captur
glycoprotein
therefor
yield
signific
list
glycoprotein
serumplasma
close
correl
glycoprotein
profil
observ
serum
plasma
except
absenc
fibrinogen
found
plasma
result
clot
process
glycoprotein
profil
three
ethnic
specimen
caucasian
american
asian
american
african
american
found
similar
except
higher
angiotensinogen
level
lower
histidinerich
glycoprotein
level
caucasian
american
sampl
lower
vitronectin
level
african
american
blood
sampl
use
lac
isol
intact
glycoprotein
glycopeptid
proteolyt
digest
enhanc
identif
glycoprotein
use
affin
captur
step
lcmsm
total
nglycosyl
site
protein
human
serum
identifi
sec
also
found
use
signific
enrich
nlink
glycopeptid
rel
nonglycosyl
peptid
nlink
glycan
express
tryptic
glycopeptid
contribut
substanti
mass
recent
new
approach
base
hydrazid
chemistri
coval
captur
glycoprotein
report
broad
analysi
human
plasma
nglycoprotein
follow
enzymat
digest
nlink
glycopeptid
nglycosidas
f
lcmsm
analysi
deglycosyl
peptid
result
identif
total
nglycopeptid
repres
nonredund
nglycoprotein
glycoprotein
pulldown
method
incorpor
stabl
isotop
label
quantit
analysi
glycoprotein
serum
use
msm
method
lcmsm
malditoftofm
serial
lac
coupl
stabl
isotop
label
global
intern
standard
quantif
strategi
report
compar
analysi
sialyl
glycoform
protein
contain
differenti
branch
complextyp
glycan
rel
degre
sialyl
among
human
serum
glycoprotein
separ
glycosyl
site
within
protein
character
compar
lowdens
lipoprotein
ldl
plasma
isol
twostep
discontinu
densitygradi
ultracentrifug
identifi
use
malditofm
lcmsm
addit
domin
apo
ldl
found
contain
number
apolipoprotein
apo
cii
apo
ciii
apo
e
apo
ai
apo
aiv
apo
j
apo
serum
amyloid
aiv
calgranulin
lysozym
c
isoform
analysi
protein
composit
ldl
may
contribut
reveal
role
atherogenesi
mechan
lead
coronari
diseas
human
highdens
lipoprotein
hdl
abund
lipoprotein
particl
plasma
neg
risk
factor
atherosclerosi
use
similar
approach
ldl
protein
hdl
found
contain
follow
protein
apo
ai
apo
aii
apo
aiv
apo
ci
apo
cii
apo
ciii
apo
e
apo
saa
salivari
alphaamylas
apo
l
similarli
mani
apoprotein
exhibit
differ
isoform
multipl
glycosyl
form
apo
ai
apo
aii
observ
quantit
proteom
profil
key
step
reveal
differenti
express
protein
peptid
associ
diseas
state
initi
malditofm
selditofm
consid
promis
clinic
tool
provid
fast
highthroughout
analysi
compat
clinic
set
howev
concern
reproduc
coverag
techniqu
maldim
profil
serum
plasma
protein
peptid
usual
requir
spe
pretreat
preenrich
function
bead
particl
numer
studi
report
use
selditofm
differ
function
proteinchip
diseas
detect
mainli
base
distinct
proteom
pattern
question
rais
regard
reproduc
accuraci
mass
rang
dynam
rang
seldim
method
multilaboratori
studi
conduct
address
issu
lcm
profil
repres
one
labelfre
method
rel
quantif
protein
method
requir
comparison
ident
proteolyt
peptid
two
experi
accur
determin
rel
ratio
protein
reli
accuraci
mass
measur
chromatograph
reproduc
although
rel
quantif
monitor
chang
protein
abund
two
condit
determin
absolut
quantiti
protein
therefor
informat
tool
requir
align
lcm
data
number
factor
need
consid
denois
mass
charg
state
estim
chromatograph
reproduc
peptid
quantif
via
integr
extract
ion
chromatogram
opensourc
softwar
suit
specarray
recent
introduc
gener
visual
peptid
array
signal
lcm
dataset
provid
use
softwar
platform
quantit
lcm
profil
lcm
also
test
absolut
quantif
protein
without
requir
use
extern
refer
peptid
singl
point
calibr
obtain
mass
spectromet
applic
subsequ
absolut
quantif
protein
within
complex
mixtur
multidimension
lcmsm
demonstr
identif
protein
significantli
increas
concentr
follow
vivo
lipopolysaccharid
lp
administr
includ
inflammatori
acutephas
protein
ceesim
promis
tool
profil
plasmaserum
peptid
high
resolv
power
ce
allow
polypeptid
display
within
min
singl
analysi
run
automat
deconvolut
normal
spectra
import
extract
quantit
inform
cem
spectra
peptid
profil
perform
use
differenti
peptid
display
dpd
method
offlin
combin
rplc
maldim
cem
dpd
applic
clinic
peptidom
analysi
consid
method
fast
reproduc
dige
requir
singl
gel
reproduc
detect
differ
two
protein
sampl
realiz
tag
two
sampl
two
differ
fluoresc
dye
run
gel
postrun
fluoresc
imag
gel
two
imag
superimpos
imag
dige
use
resolv
approxim
protein
spot
crude
serum
wherea
protein
spot
visual
follow
remov
six
highabund
protein
new
method
term
intactprotein
analysi
system
ipa
coupl
cy
dye
label
report
quantit
profil
human
plasma
proteom
follow
immunodeplet
pair
plasma
sampl
label
differ
cy
dye
subsequ
separ
multipl
dimens
accord
charg
hydrophob
molecular
mass
differ
abund
resolv
protein
determin
base
cy
dye
ratio
ipa
provid
highli
sensit
quantit
approach
analysi
serum
plasma
protein
quantit
proteom
use
stabl
isotop
tag
autom
msm
emerg
techniqu
potenti
clinic
applic
malditoftofm
use
isotopelabel
refer
peptid
proven
highthroughput
method
serum
biomark
screen
use
postdigest
trypsincatalyz
peptid
label
lcfticr
ms
accur
mass
time
tag
strategi
total
plasma
protein
quantifi
follow
lp
administr
includ
protein
significantli
chang
prior
h
lp
treatment
new
method
term
ingel
stableisotop
label
isil
protein
initi
resolv
gel
electrophoresi
ge
gel
slice
interest
react
separ
light
versu
heavi
isotopelabel
reagent
mix
digest
proteas
result
peptid
final
analyz
lcm
ms
protein
identif
quantif
advantag
isil
visual
gel
differ
use
first
quantif
step
follow
accur
sensit
protein
level
stableisotop
label
msbase
rel
quantif
immunoassay
commonli
use
valid
proteom
biomark
howev
develop
assay
hamper
need
specif
antibodi
antigen
protein
interest
furthermor
calibr
curv
immunoassay
inher
nonlinear
crossvalid
almost
unavoid
quantit
ms
analysi
use
multipl
reaction
monitor
mrm
demonstr
accur
analysi
target
protein
may
serv
power
tool
valid
purpos
although
mrm
demonstr
quantif
low
abund
serum
protein
prostat
antigen
psa
still
concern
regard
sensit
assay
compar
exist
immunoassay
order
quantifi
low
abund
protein
serum
method
term
stabl
isotop
standard
captur
antipeptid
antibodi
siscapa
recent
introduc
use
antipeptid
antibodi
immobil
nanoaffin
column
enrich
specif
peptid
along
spike
stableisotopelabel
intern
standard
method
appear
suitabl
quantif
low
abund
protein
find
applic
valid
diagnost
protein
panel
larg
sampl
set
protein
array
solidphas
ligandbind
assay
system
use
immobil
protein
surfac
glass
cellulos
membran
mass
spectromet
plate
microbead
micronanoparticl
assay
highli
parallel
often
miniatur
main
advantag
protein
array
includ
highthroughput
exquisit
sensit
minut
sampl
requir
analysi
howev
express
purif
captur
protein
especi
antibodi
cumbersom
design
captur
array
particularli
screen
complex
sampl
also
need
take
consider
problem
crossreact
common
format
protein
array
antibodi
array
antibodi
physic
coval
immobil
surfac
detect
target
molecul
complex
sampl
serum
experiment
format
antibodi
array
broadli
categor
two
class
direct
label
experi
ii
dual
antibodi
sandwich
assay
direct
label
method
coval
label
protein
complex
mixtur
provid
mean
detect
bound
protein
incub
antibodi
microarray
protein
label
tag
biotin
signal
bound
protein
amplifi
twocolor
rollingcircl
amplif
rca
method
antibodi
microarray
develop
measur
rel
level
protein
captur
array
two
serum
sampl
label
biotin
digoxigenin
respect
twocolor
rca
produc
fluoresc
higher
directlabel
indirectdetect
method
antibodi
microarray
provid
sensit
analysi
low
abund
serum
protein
sandwich
assay
cytokin
elisa
array
protein
captur
antibodi
microarray
detect
cocktail
detect
antibodi
antibodi
match
one
spot
antibodi
sandwichbas
array
extrem
sensit
low
abund
cytokin
growth
factor
correct
use
interpret
antibodi
microarray
data
requir
proper
normal
data
recent
studi
compar
seven
differ
normal
method
antibodi
microarray
analysi
suggest
normal
elisadetermin
concentr
igm
result
accur
reproduc
reliabl
data
antibodi
array
serum
profil
well
demonstr
human
diseas
cancer
analysi
serum
sampl
use
microarray
contain
antibodi
indic
serum
von
willebrand
factor
igm
villin
igg
significantli
differ
prostat
cancer
control
subject
analysi
sera
pancreat
cancer
patient
use
twocolor
rca
microarray
reveal
differenti
express
creactiv
protein
crp
saa
iga
proteininduc
vitamin
k
antagonistii
upregul
plasma
gelsolin
downregul
similarli
crp
saa
mucin
found
overexpress
lung
cancer
sera
use
twocolor
rca
array
fabric
nccoat
slide
serum
test
array
contain
mab
cancer
carcinoembryon
antigen
cea
alphafetoprotein
afp
psa
freepsa
human
growth
hormon
betahuman
chorion
gonadotropin
neuronspecif
enolas
nse
ferritin
yield
overal
sensit
cancer
patient
high
sensit
liver
pancrea
ovarian
tumor
low
sensit
gastrointestin
tumor
specif
healthi
individu
test
applic
array
physic
checkup
individu
result
case
subsequ
confirm
cancer
autoantigen
array
appear
use
analysi
character
serum
autoantibodi
autoimmun
diseas
array
contain
major
autoantigen
eight
distinct
human
autoimmun
diseas
construct
provid
power
tool
studi
specif
pathogenesi
autoantibodi
respons
identifi
defin
relev
autoantigen
autoimmun
diseas
glomerular
proteom
array
antigen
known
express
glomerular
milieu
construct
studi
serum
autoantibodi
lupu
human
lupu
sera
display
two
distinct
igm
autoantibodi
cluster
one
reactiv
dna
polyreact
antigen
array
promis
uncov
novel
autoantibodi
diseas
associ
distinguish
patient
highrisk
recent
novel
phage
protein
array
use
phagedisplay
librari
deriv
prostatecanc
tissu
develop
detect
serum
autoantibodi
signatur
prostat
cancer
construct
phagedisplay
librari
prostatecanc
peptid
mrna
isol
prostatecanc
tissu
six
patient
clinic
local
diseas
insert
cdna
fragment
phage
system
peptid
encod
prostat
cancer
cdna
express
display
surfac
phage
fuse
ctermin
capsid
protein
phage
surfac
complex
function
bait
captur
autoantibodi
serum
predict
model
yield
specif
discrimin
prostat
cancer
control
recombinantpurifi
allergen
microarray
promis
profil
diseaseelicit
allergen
eg
quantit
measur
serum
allergenspecif
ige
level
type
allergi
allergen
microarray
contain
purifi
allergen
molecul
repres
common
allergen
sourc
develop
monitor
allerg
patient
ige
reactiv
profil
larg
number
diseasecaus
allergen
use
minut
amount
serum
microarray
test
provid
equival
perform
elisa
test
offer
signific
advantag
conveni
cost
compar
tradit
allergi
test
format
protein
array
use
hepat
b
c
viru
hbv
hcv
antigen
also
describ
detect
hbv
hcv
antibodi
patient
sera
arraybas
assay
offer
opportun
serodiagnosi
infecti
diseas
allow
simultan
measur
specif
subclass
antibodi
direct
pathogen
antigen
array
format
use
serum
protein
analysi
includ
selfassembl
monolay
array
filtrationbas
array
multiplex
photoaptamerbas
array
phagebas
array
rp
array
filtrationbas
protein
array
improv
overal
reaction
kinet
rate
tenfold
enhanc
sensit
specif
assay
rp
array
serum
sampl
spot
microarray
screen
content
specif
serum
protein
singl
experi
use
targetrecogn
antibodi
fluoresc
label
secondari
antibodi
photoaptamerbas
array
util
photoaptam
coval
bind
target
analyt
fluoresc
signal
detect
array
vigor
wash
remov
background
protein
provid
superior
sensit
lod
fm
low
abund
protein
vegf
endostatin
bottleneck
fabric
protein
array
especi
global
measur
product
huge
divers
purifi
protein
eg
antibodi
protein
array
contain
nonredund
purifi
human
fusion
protein
polym
surfac
develop
profil
antibodi
repertoir
serum
autoimmun
diseas
patient
studi
point
new
sourc
produc
thousand
purifi
protein
protein
array
fabric
peptid
microarray
display
biolog
activ
small
peptid
highdens
format
provid
attract
techniqu
probe
complex
sampl
serum
technic
difficulti
fabric
peptid
array
peptid
usual
small
molecular
mass
easili
access
adsorb
onto
solid
support
peptid
also
lack
welldefin
structur
therefor
correct
orient
essenti
promot
interact
peptid
target
incorpor
elong
spacer
molecul
modif
solid
substrat
significantli
improv
access
target
molecul
addit
protein
array
also
prepar
cellular
protein
express
cell
line
protein
express
cellfre
vitro
transcriptiontransl
system
one
major
applic
serum
proteom
analysi
discov
biomark
human
cancer
detect
although
tumor
marker
routin
measur
clinic
oncolog
valu
cancer
detect
controversi
larg
singl
tumor
marker
sensit
specif
enough
meet
stringent
diagnost
criteria
one
strategi
overcom
shortcom
singl
tumor
biomark
measur
combin
proteom
biomark
enhanc
sensit
specif
analysi
serum
proteom
varieti
cancer
patient
led
discoveri
number
put
marker
tabl
futur
valid
candid
larg
independ
patient
cohort
need
accomplish
use
quantit
assay
elisa
lcmrm
ms
studi
list
tabl
perform
use
ms
seldim
new
advanc
quantit
proteom
may
expect
applic
isotop
taggingmsm
labelfre
lcm
cem
method
serum
biomark
discoveri
addit
aberr
glycosyl
protein
known
close
associ
cancer
progress
consid
mani
clinic
biomark
therapeut
target
glycoprotein
eg
cea
psa
etc
quantit
serum
glycoproteom
analysi
use
affin
captur
agent
isotop
label
could
promis
approach
search
cancer
biomark
candid
marker
discov
serum
acut
phase
protein
commonli
share
among
differ
cancer
protein
rel
abund
also
overexpress
human
diseas
eg
autoimmun
diseas
impli
current
serum
proteom
analysi
far
comprehens
new
proteom
technolog
enhanc
resolv
power
unmask
low
abund
protein
may
forese
sensit
specif
serum
protein
marker
human
cancer
analysi
blood
sampl
patient
suffer
autoimmun
diseas
remain
mainstay
clinic
initi
diagnosi
prognost
clinic
decisionmak
serum
proteom
analysi
reveal
peptid
protein
eg
crp
calgranulin
b
c
diagnost
valu
rheumatoid
arthriti
ra
multipl
sclerosi
meanwhil
test
presenc
serum
autoantibodi
proven
confirmatori
assay
autoimmun
diseas
instanc
serum
autoantibodi
alphaenolas
found
earli
ra
patient
actin
alphaenolas
atp
synthas
found
celiac
diseas
patient
serum
autoantibodi
triosephosph
isomeras
tpi
predominantli
detect
osteoarthr
oa
compar
ra
system
lupu
erythematosu
sle
alter
protein
hbv
infect
sera
found
hg
beta
chain
apo
ai
aiv
transthyretin
ttr
dna
topoisomeras
ii
beta
alter
protein
display
quantiti
also
pattern
seldim
analysi
sera
chronic
hepat
b
liver
fibrosi
liver
cirrhosi
nonalcohol
fatti
liver
diseas
patient
suggest
distinct
proteom
pattern
capabl
differenti
among
differ
stage
fibrosi
predict
fibrosi
cirrhosi
deglycosyl
serum
protein
may
result
simplif
serum
proteom
profil
enhanc
resolut
compar
proteom
analysi
serum
amyloid
p
compon
ceruloplasmin
appar
denglycosyl
shown
correl
hbv
diseas
golgi
protein
glycoprotein
found
elev
hyperfucosyl
sera
patient
hepatocellular
carcinoma
may
assist
earli
detect
hbvinduc
liver
cancer
heart
diseas
lead
caus
mortal
morbid
human
biomark
need
diagnosi
prognosi
therapeut
monitor
risk
stratif
acut
injuri
acut
myocardi
infarct
ami
chronic
heart
diseas
serum
apo
ai
apo
aii
glycosyl
product
found
differenti
express
atherosclerosi
patient
normal
control
use
seldim
maldim
analysi
peptid
sera
normal
ami
subject
produc
characterist
pattern
could
provid
accur
diagnosi
ami
serum
alphabcrystallin
tropomyosin
discov
valid
valuabl
biomark
cardiac
allograft
reject
diagnosi
stroke
mainli
reli
neurolog
assess
patient
use
neuroimag
techniqu
includ
comput
tomographi
andor
magnet
reson
imag
scan
earli
diagnost
marker
stroke
ideal
capabl
discrimin
ischem
hemorrhag
stroke
would
consider
improv
patient
acut
manag
serum
heartfatti
acidbind
protein
discov
valid
marker
earli
diagnosi
stroke
consider
better
diagnost
valu
nse
seldim
analysi
elisa
valid
indic
apo
ci
apo
ciii
level
plasma
could
distinguish
hemorrhag
ischem
stroke
two
adjac
studi
indic
seldim
might
use
techniqu
detect
emerg
infecti
diseas
sever
acut
respiratori
syndrom
sar
first
studi
nine
protein
found
significantli
increas
three
protein
found
significantli
decreas
sar
patient
includ
protein
identifi
saa
second
studi
discriminatori
classifi
panel
four
biomark
report
sensit
specif
sar
detect
classifi
could
also
distinguish
acut
sar
fever
influenza
specif
cn
shield
system
influenc
two
separ
barrier
bloodbrain
barrier
bbb
bloodtocerebrospin
barrier
bcb
failur
either
barrier
bear
profound
signific
etiolog
diagnosi
sever
neurolog
diseas
compar
proteom
analysi
sera
patient
undergo
bbb
disrupt
bbbd
prebbb
open
serum
indic
ttr
correl
bbbd
may
peripher
tracer
bcb
alzheim
diseas
ad
patient
serum
protein
hg
hemoglobin
vitronectin
glycoprotein
apo
fragment
factor
h
histidinerich
glycoprotein
found
alter
level
aldolas
suggest
common
autoantigen
ad
might
serv
new
target
potenti
immun
modul
discrimin
pattern
analysi
carrierproteinbound
serum
peptid
use
maldi
orthogon
tofm
success
classifi
ad
patient
control
subject
high
sensit
specif
serum
protein
includ
hg
hemoglobin
fibrinogen
ttr
proplatelet
basic
protein
complement
inhibitor
found
alter
level
patient
suffer
insulin
diabet
small
dens
ldl
diabet
patient
found
enrich
apo
ciii
deplet
apo
ci
apo
ai
apo
e
compar
match
healthi
control
serum
proteom
pattern
analysi
could
use
evalu
period
hemodialysi
treatment
assess
remiss
activ
wegen
granulomatosi
base
blot
approach
immunoreact
protein
speci
detect
system
candidiasi
patient
serum
specimen
approach
may
use
diagnosi
clinic
followup
fungal
infect
urin
less
complex
serum
rel
high
thermodynam
stabil
promis
studi
medium
discoveri
novel
biomark
mani
human
diseas
bladder
cancer
renal
diseas
optim
sampl
prepar
necessari
first
step
urinari
proteom
analysi
sampl
desalt
use
spe
precipit
dialysi
often
requir
aceton
appear
precipit
acid
hydrophil
protein
wherea
ultracentrifug
fraction
basic
hydrophob
membran
protein
effici
precipit
urinari
protein
vari
among
differ
organ
solvent
highest
recoveri
rate
urinari
protein
obtain
ethanol
lowest
one
acet
acid
acnprecipit
urin
sampl
produc
greatest
number
spot
gel
wherea
aceticprecipit
sampl
yield
smallest
number
spot
standard
shotgun
analysi
use
combin
lcmsm
direct
lcmsm
lcmsm
result
identif
total
protein
urinari
proteom
similar
serum
proteom
analysi
prefraction
immunodeplet
help
unmask
low
abund
protein
urin
simpl
prefraction
base
molecular
weight
cutoff
follow
immunodeplet
albumin
igg
yield
distinct
gel
spot
uniqu
protein
identifi
includ
plasma
protein
microbead
coat
hexamer
peptid
ligand
librari
greatli
enhanc
identif
urin
protein
drastic
reduc
level
abund
speci
strongli
concentr
dilut
rare
one
recent
studi
reveal
membran
protein
cytosol
protein
renal
epithelia
highli
enrich
lowdens
urinari
structur
identifi
exosom
exosom
membran
vesicl
origin
intern
vesicl
multivesicular
bodi
nanolcmsm
analysi
perform
identifi
protein
urinari
exosom
includ
multipl
protein
known
respons
renal
system
diseas
therefor
urinari
exosom
may
rich
sourc
diseas
biomark
discoveri
urin
human
urin
proteom
contain
larg
array
peptid
profil
cem
lcm
dpd
lcmalditofm
selditofm
offer
simpl
platform
highthroughput
urin
profil
howev
standard
analysi
condit
critic
extrins
intrins
factor
must
taken
account
accur
data
interpret
biomolecular
interact
analysi
ms
biam
chipbas
analyt
techniqu
base
quantit
measur
interact
surfaceimmobil
ligand
solut
analyt
surfac
plasmon
reson
spr
sens
well
malditofm
analysi
analyt
affinitycaptur
sensor
surfac
techniqu
may
use
rapid
screen
urinari
protein
indic
put
biomark
renal
dysfunct
diseas
diagnost
use
urin
proteom
biomark
attract
urin
test
simpl
noninvas
urin
proteom
analysi
toward
discoveri
bladder
cancer
biomark
clearli
demonstr
use
selidtofm
approach
put
marker
discov
bladder
cancer
includ
urinari
psoriasin
calreticulin
crt
gammasynuclein
sncg
catecholomethyltransferas
comt
orosomucoid
matrix
fibronectin
fragment
combin
crt
sncg
comt
exhibit
overal
sensit
specif
pointofcar
proteom
assay
report
measur
nuclear
matrix
protein
urin
could
enhanc
detect
malign
patient
risk
factor
symptom
bladder
cancer
sensit
specif
assay
determin
respect
urin
proteom
analysi
may
potenti
unravel
marker
cancer
includ
prostat
renal
lung
ovarian
origin
urin
marker
prostat
cancer
may
overcom
limit
serum
psa
improv
overal
specif
diagnosi
routin
use
circul
marker
renal
cancer
often
detect
incident
frequent
advanc
time
present
half
patient
local
distant
tumor
spread
selditofm
profil
neuralnetwork
analysi
abl
detect
renal
cancer
sensit
specif
howev
assay
test
new
independ
patient
cohort
month
later
sensit
specif
declin
remark
rang
eosinophilderiv
neurotoxin
edn
especi
glycosyl
form
edn
osteopontin
fragment
found
elev
urin
ovarian
cancer
patient
combin
modifi
edn
osteopontin
fragment
show
specif
sensit
earli
stage
ovarian
cancer
increas
interest
develop
urin
biomark
detect
renal
allograft
reject
altern
percutan
needl
biopsi
costli
associ
signific
patient
morbid
mortal
seldim
profil
indic
predominantli
small
urin
peptid
protein
kda
could
distinguish
renal
transplant
patient
reject
acut
reject
patient
acut
tubulointerstiti
reject
also
express
higher
level
cleav
urin
distinct
urinari
proteom
pattern
obtain
cem
seldim
labelfre
lcm
profil
demonstr
earli
detect
renal
diseasescompl
cem
studi
differenti
excret
polypeptid
form
pattern
earli
indic
graftversushost
diseas
gvhd
allow
discrimin
gvhd
patient
without
complic
specif
sensit
crossvalid
similar
cem
method
also
appli
assess
renal
damag
patient
type
ii
diabet
well
patient
iga
nephropathi
largescal
proteom
studi
quantit
proteom
isotopecod
affin
tag
icat
lcmsm
approach
use
compar
urinari
proteom
patient
dent
diseas
normal
subject
sever
vitamin
prosthet
group
carrier
protein
apolipoprotein
complement
compon
found
higher
level
dent
urin
compar
normal
urin
suggest
protein
reabsorb
effici
class
protein
convers
protein
renal
origin
found
proportion
higher
amount
normal
urin
urinari
proteom
chang
associ
interstiti
bacteri
cystiti
urolithiasi
pancreat
also
investig
differenti
express
pancreat
secretori
trypsin
inhibitor
proteolyt
fragment
observ
patient
pancreat
normal
control
subject
suggest
possibl
role
protein
caus
hereditari
pancreat
csf
secret
sever
differ
cn
structur
chang
protein
composit
csf
may
indic
alter
brain
protein
express
neurodegen
cn
disord
analysi
brainspecif
protein
csf
complic
fact
csf
protein
deriv
plasma
highli
abund
protein
tend
obscur
less
abund
protein
addit
total
protein
concentr
csf
low
mgml
deplet
highli
abund
protein
sampl
preenrich
desalt
eg
precipit
ultrafiltr
often
requir
prior
csf
proteom
analysi
two
immunodeplet
method
igi
antibodi
microbead
marc
recent
evalu
igi
antibodi
microbead
remov
six
csf
protein
hsa
transferrin
igg
iga
igm
fibrinogen
wherea
marc
remov
hsa
transferrin
igg
iga
hg
comparison
indic
marc
remov
major
protein
effect
approxim
spot
visual
compar
gel
csf
without
protein
deplet
identif
csf
protein
perform
use
gelfre
approach
cefticr
ms
lcfticr
ms
lcmsm
total
protein
identifi
csf
ten
subject
use
immunodeplet
pretreat
peptid
lcmsm
protein
uniqu
individu
subject
wherea
common
among
ten
subject
suggest
consider
subjecttosubject
variabl
csf
proteom
quantit
proteom
use
icat
appli
compar
analysi
csf
protein
younger
adult
older
adult
csf
protein
identifi
protein
exhibit
chang
concentr
older
younger
individu
data
suppli
necessari
inform
appropri
interpret
protein
biomark
agerel
neurodegen
diseas
use
ultrafiltr
spe
lmw
csf
fraction
mw
kda
prepar
analyz
capillari
lcquadrupol
tof
qtof
ms
lead
identif
peptid
deriv
protein
character
ptm
csf
protein
contribut
understand
molecular
event
occur
homeostat
patholog
process
cn
four
csf
protein
complement
gammachain
gelsolin
ceruloplasmin
identifi
phosphotyrosyl
protein
use
combin
ge
western
blot
immunoprecipit
follow
immunodeplet
abund
csf
protein
hsa
transferrin
igg
iga
igm
fibrinogen
hg
specif
fluoresc
stain
use
map
phosphoprotein
glycoprotein
subsequ
ingel
digest
lcmsm
analysi
result
identif
phosphoprotein
glycoprotein
csf
identif
csf
biomark
neurolog
disord
would
great
valu
clinician
difficulti
earli
differenti
diagnos
diseas
clinic
practic
earli
diagnosi
degen
diseas
import
initi
symptomat
treatment
even
greater
signific
drug
potenti
slow
degen
process
prove
clinic
effect
use
specif
csf
marker
discrimin
ad
control
neurolog
diseas
improv
simultan
analysi
betaamyloid
totaltau
phosphoryl
tau
combin
low
level
csfbetaamyloid
high
level
csftau
csfphosphotau
associ
ad
diagnosi
may
strengthen
recent
discoveri
number
put
csf
marker
includ
apo
apo
e
apo
j
retinolbind
protein
rbp
kininogen
cell
cycl
progress
eight
protein
glycoprotein
betaglycoprotein
cathepsin
b
amyloid
precursor
complement
protein
glutathion
independ
prostaglandin
synthas
develop
protein
new
biomark
may
lead
earli
diagnosi
ad
provid
use
inform
drug
trial
anoth
observ
proteom
studi
investig
csf
protein
possibl
biomark
may
use
compar
individu
protein
isoform
express
level
addit
commonli
measur
total
protein
express
level
frontotempor
dementia
ftd
refer
group
rare
brain
disord
affect
frontal
tempor
lobe
brain
control
speech
person
studi
reveal
six
csf
protein
graninlik
neuroendocrin
precursor
pigmentepitheliumderiv
factor
rbp
apo
hg
albumin
significantli
alter
ftd
compar
control
sever
protein
involv
ftd
patholog
influenc
csf
ad
patient
vice
versa
establish
differ
pathophysiolog
mechan
ftd
ad
sinc
ftd
commonli
misdiagnos
ad
differenti
express
protein
may
use
indic
distinguish
ftd
ad
two
common
neurodegen
disord
ms
autoimmun
inflammatori
demyelin
diseas
cn
diseas
mechan
ms
molecular
level
remain
poorli
understood
diagnosi
ms
challeng
lack
specif
diagnost
test
csf
protein
cartilag
acid
protein
tetranectin
sparclik
protein
autotaxin
cleavag
product
cystatin
c
could
potenti
marker
ms
diagnosi
predominantli
identifi
ms
patient
patient
nonm
inflammatori
cn
disord
creutzfeldtjakob
diseas
cjd
rare
degen
invari
fatal
brain
disord
belong
famili
human
anim
diseas
known
transmiss
spongiform
encephalopathi
tse
prion
diseas
diagnosi
cjd
base
clinic
electroencephalograph
criteria
practic
reliabl
premortem
test
cjd
relat
tse
earli
studi
immunoassay
suggest
protein
level
cjd
patient
csf
correl
nse
level
therefor
might
serv
marker
cjd
diseas
followup
studi
blot
reveal
multipl
isoform
protein
beta
gamma
epsilon
eta
present
csf
patient
cjd
specif
isoform
pattern
could
use
differenti
cjd
neurodegen
diseas
panel
seven
csf
protein
includ
apo
e
found
capabl
distinguish
ant
mortem
variant
cjd
ant
mortem
sporad
cjd
cellular
prion
protein
prpc
glycosylphosphatidylinositolanchor
glycoprotein
repres
substrat
gener
conform
pathogen
isoform
prpsc
prion
diseas
incred
microheterogen
prpc
human
csf
western
spot
observ
presum
result
prpc
glycosyl
isoform
well
ntermin
truncat
fragment
amyotroph
later
sclerosi
al
neurodegen
disord
character
degener
motor
neuron
two
csf
protein
ttr
cystatin
c
found
downregul
wherea
carboxytermin
fragment
neuroendocrin
protein
found
upregul
csf
al
patent
compar
control
two
isoform
express
higher
level
patient
lowgrad
glioma
compar
control
group
consist
patient
mix
neurolog
diagnos
one
patient
level
ahsg
significantli
reduc
gross
total
resect
tumor
two
tumorrel
protein
nmyc
oncoprotein
lowmolecular
weight
caldesmon
identifi
csf
sampl
patient
primari
brain
tumor
csf
patient
suffer
hiv
chronic
fatigu
syndrom
cf
preeclampsia
cerebr
autosom
domin
arteriopathi
subcort
infarct
leukoencephalopathi
also
investig
assess
csf
fluid
cf
persian
gulf
war
ill
pgi
fibromyalgia
patient
lcqtofm
suggest
csf
proteom
presum
patholog
mechan
might
share
among
disord
although
syndrom
name
definit
differ
human
saliva
secret
multipl
salivari
gland
includ
parotid
submandibular
sm
sublingu
sl
minor
gland
lie
beneath
oral
mucosa
saliva
contain
larg
array
protein
mani
inform
human
diseas
detect
group
one
three
group
recent
fund
nation
institut
dental
craniofaci
research
conduct
human
salivari
proteom
project
wwwhsppuclaedu
envis
catalog
human
salivari
proteom
avail
one
begin
examin
compar
salivari
proteom
high
impact
diseas
cancer
diabet
autoimmun
diseas
numer
studi
perform
identifi
saliva
protein
use
signific
number
spot
typic
saliva
gel
actual
correspond
amylas
cystatin
ig
therefor
deplet
amylas
ig
prior
analysi
improv
map
identif
saliva
protein
compar
shotgun
proteom
analysi
base
advanc
msm
technolog
qtof
linear
lit
litorbitrap
provid
significantli
enhanc
power
identif
saliva
protein
ffe
cief
success
coupl
litm
analysi
lead
identif
protein
respect
whole
saliva
addit
specif
subgroup
saliva
protein
prolinerich
protein
prp
histatin
cystatin
independ
identifi
character
rel
quantit
saliva
lmw
peptid
also
demonstr
use
isotop
tag
rel
absolut
quantit
itraq
malditoftof
similar
plasmaserum
mani
protein
eg
mucin
human
saliva
glycosyl
lectinbind
assay
page
gel
appear
use
character
saliva
glycoprotein
associ
oral
diseas
sjogren
syndrom
ss
gem
well
demonstr
character
salivari
glycoprotein
glycoform
glycan
structur
eg
oglycan
releas
reduct
betaelimin
recent
profil
saliva
glycoprotein
use
glycoprotein
pulldown
strategi
base
hydrazid
chemistri
total
identifi
distinct
glycopeptid
repres
distinct
glycoprotein
human
whole
saliva
saliva
attract
medium
diseas
diagnosi
saliva
test
sever
key
advantag
includ
minimum
cost
noninvas
easi
sampl
collect
process
saliva
protein
may
diagnost
valu
human
oral
system
diseas
instanc
solubl
fragment
oncogen
ca
found
significantli
upregul
saliva
sampl
breast
cancer
patient
healthi
control
patient
benign
tumor
elev
level
salivari
cea
tnfalpha
detect
patient
oral
cancer
studi
base
immunoassay
individu
gene
product
proteom
biomark
combin
expect
enhanc
sensit
specif
human
cancer
detect
salivari
protein
marker
well
demonstr
diagnosi
ss
autoimmun
diseas
character
xerostomia
dri
mouth
xerophthalmia
dri
eye
saliva
autoantibodi
eg
antirossa
antilassb
antialphafodrin
appli
ss
detect
clinic
set
recent
parotid
salivari
marker
discov
ss
use
selditofm
compar
nonss
subject
parotid
lactoferrin
igg
kappa
light
chain
polymer
ig
receptor
lysozym
c
cystatin
c
found
significantli
increas
wherea
two
prolinerich
protein
amylas
carbon
anhydras
vi
found
significantli
decreas
patient
group
candid
remain
valid
ideal
salivari
marker
would
capabl
differenti
ss
autoimmun
diseas
balf
obtain
fiberopt
bronchoscopi
biofluid
mirror
express
normal
secret
pulmonari
protein
product
activ
cell
destruct
process
balf
present
common
way
sampl
compon
epitheli
line
fluid
faith
reflect
protein
composit
pulmonari
airway
character
proteom
within
compart
provid
opportun
establish
tempor
prognost
indic
airway
diseas
commonli
use
balf
proteom
analysi
presum
mani
balf
protein
structur
modifi
andor
truncat
due
proteolysi
continu
effort
develop
refer
map
human
balf
protein
current
master
gel
balf
protein
compris
spot
visual
silver
stain
identif
protein
gel
initi
perform
use
immunoblot
edman
sequenc
match
refer
gel
significantli
improv
use
advanc
ms
identif
techniqu
largescal
proteom
analysi
use
immunoaffin
deplet
sdspage
fraction
protein
ingel
digest
subsequ
nanolcmsm
report
identif
semiquantit
distinct
protein
balf
around
protein
display
signific
upregul
specif
asthmat
patient
segment
allergen
challeng
differenti
express
protein
repres
wide
spectrum
function
class
major
express
chang
close
associ
mani
aspect
pathophysiolog
asthma
larg
portion
newli
identifi
protein
balf
provid
new
insight
find
novel
patholog
mediat
biomark
asthma
analysi
balf
proteom
discoveri
diseaseassoci
protein
contribut
better
knowledg
lung
structur
molecular
level
studi
lung
disord
clinic
level
although
balf
protein
reflect
great
divers
cellular
origin
function
compar
analysi
serum
balf
proteom
reveal
protein
abund
balf
plasma
suggest
specif
produc
airway
protein
therefor
good
candid
becom
lungspecif
diseas
biomark
major
balf
proteom
studi
dedic
fibros
interstiti
lung
diseas
patient
sarcoidosi
inflammatori
lung
diseas
exhibit
alter
balf
proteom
profil
mani
protein
alter
level
identifi
nonplasma
protein
involv
inflammatori
oxidantantioxid
process
differenti
balf
proteom
profil
observ
patient
suffer
sarcoidosi
idiopath
pulmonari
fibrosi
ipf
two
form
interstiti
lung
diseas
character
differ
pathogenesi
clinic
evolut
sarcoidosi
patient
exhibit
higher
amount
plasma
protein
ipf
patient
show
signific
higher
level
lmw
protein
either
involv
inflammatori
process
eg
calgranulin
antioxid
respons
eg
antioxid
peroxysom
enzym
thioredoxin
peroxidas
compar
analysi
balf
patient
sarcoidosi
ipf
system
sclerosi
reveal
carbonyl
protein
upregul
balf
diseas
patient
greater
number
protein
target
oxid
present
balf
ipf
patient
predict
oxygenderiv
free
radic
produc
phagocyt
may
contribut
lung
tissu
damag
occur
diffus
lung
diseas
monitor
proteolyt
chang
structur
modifi
pattern
balf
protein
lung
diseas
may
provid
insight
diseas
mechan
diagnost
potenti
lung
disord
known
associ
consider
modif
surfact
composit
proteolyt
deriv
surfact
protein
spa
import
innat
host
defens
compon
lung
found
present
balf
cystic
fibrosi
cf
patient
present
control
use
highresolut
fticr
ms
analysi
surfact
protein
spa
spd
includ
structur
modifi
truncat
form
identifi
balf
patient
cf
chronic
bronchiti
pulmonari
alveolar
proteinosi
chang
balf
proteom
profil
may
reflect
associ
state
asthma
alter
level
cystatin
igbf
ttr
observ
individu
suffer
upper
airway
irrit
asthma
gelsolin
secret
found
increas
threefold
airway
surfac
liquid
epithelia
treat
suggest
gelsolin
might
improv
fluiditi
airway
surfac
liquid
asthma
break
filament
actin
may
releas
larg
amount
die
cell
inflamm
addit
number
studi
conduct
monitor
proteom
chang
balf
patient
suffer
lupu
erythematosi
wegen
granulomatosi
lipoid
pneumonia
chronic
eosinophil
pneumonia
asbestosi
bacteri
pneumonia
hypersensit
pneumon
malign
immunosuppress
smoke
sf
thin
stringi
fluid
present
caviti
synovi
joint
reduc
friction
articular
cartilag
tissu
joint
lubric
cushion
movement
sf
may
classifi
normal
noninflammatori
inflammatori
septic
hemorrhag
group
associ
certain
diagnos
regular
sf
analysi
commonli
perform
determin
caus
acut
arthriti
sf
contain
larg
number
protein
origin
synovi
tissu
cartilag
serum
protein
composit
sf
may
reflect
pathophysiolog
condit
affect
synovi
tissu
articular
cartilag
therefor
analysi
sf
proteom
may
introduc
specif
protein
marker
earli
differenti
diagnosi
joint
diseas
ra
oa
commonli
use
differenti
map
sf
proteom
patient
differ
form
arthriti
distinct
chang
protein
pattern
observ
ra
oa
patient
alter
level
acutephas
protein
sf
observ
ra
patient
treat
antibodi
unlik
human
bodi
fluid
remov
abund
albumin
sf
sampl
significantli
improv
separ
sf
protein
lcm
screen
peptid
human
sf
indic
presenc
peptid
aglpeki
saa
deriv
saa
peptid
sever
analog
found
capabl
bind
isol
human
cd
tlymphocyt
stimul
produc
interferongamma
given
high
acutephas
serum
level
saa
massiv
proteolysi
inflammatori
relat
enzym
saaderiv
peptid
may
involv
host
defens
mechan
import
applic
sf
proteom
analysi
identifi
effect
marker
differenti
two
joint
diseas
ra
oa
put
sf
marker
discov
ra
includ
calgranulin
b
calgranulin
c
saa
myeloidrel
protein
confirm
find
calgranulin
b
examin
applic
diagnost
marker
level
calgranulin
ab
heterocomplex
plasma
sf
valid
immunoassay
patient
ra
oa
inflammatori
joint
diseas
found
plasma
level
calgranulin
ab
heterocomplex
correl
well
level
sf
henc
determin
plasma
level
could
use
distinguish
ra
patient
control
patient
inflammatori
joint
diseas
plasma
level
calgranulin
ab
heterocomplex
might
also
use
monitor
antitnfalpha
therapi
sf
protein
antitpi
autoantibodi
could
potenti
marker
oa
diagnosi
detect
predominantli
oa
patient
twostep
proteom
approach
use
identifi
valid
prognost
biomark
predict
whether
ra
patient
develop
eros
disabl
diseas
first
step
lcmsm
use
gener
protein
profil
sf
patient
either
eros
ra
noneros
ra
second
step
select
candid
verifi
use
quantit
lcmrm
ms
sera
patient
eros
ra
noneros
ra
healthi
control
lcmsm
profil
yield
total
distinct
protein
includ
crp
six
member
protein
famili
elev
sf
patient
eros
ra
quantit
lcmrm
analysi
verifi
level
crp
calgranulin
b
c
significantli
elev
serum
patient
eros
ra
compar
patient
noneros
ra
healthi
individu
nippl
aspir
noninvas
techniqu
obtain
breast
fluid
duct
open
nippl
evalu
abnorm
associ
breast
cancer
naf
contain
cell
mani
protein
eg
psa
therefor
fluid
test
malign
cell
diagnost
biomark
breast
cancer
naf
product
realiz
women
highrisk
breast
cancer
averag
total
protein
concentr
naf
naf
proteom
analysi
hold
promis
noninvas
method
identifi
biomark
breast
cancer
diagnosi
prognosi
selditofm
appli
rapid
profil
naf
sampl
search
signatur
protein
associ
differ
stage
breast
cancer
howev
ident
protein
known
concern
reproduc
reliabl
peak
quantif
use
seldim
therefor
new
algorithm
introduc
address
qualiti
control
peak
detect
quantif
selid
found
data
denois
undecim
discret
wavelet
transform
improv
reproduc
quantif
detect
peak
method
implement
ciphergen
softwar
approach
use
character
naf
proteom
discov
potenti
nsf
marker
breast
cancer
total
distinct
protein
identifi
includ
one
known
secret
three
protein
gross
cystic
diseas
fluid
protein
gcdfp
apo
propos
put
biomark
valid
confirm
significantli
alter
level
downregul
upregul
breast
cancer
recent
quantit
proteom
approach
base
icat
sdspage
lcmsm
employ
identifi
differenti
express
protein
naf
tumorbear
contralater
diseasefre
breast
patient
unilater
earlystag
breast
cancer
found
underexpress
wherea
lipophilin
b
betaglobin
hemopexin
vitamin
dbind
protein
overexpress
naf
tumorbear
breast
tf
analysi
noninvas
approach
earli
diagnosi
studi
pathogenesi
eyerel
diseas
may
also
assist
followup
assess
therapeut
treatment
eye
diseas
dri
eye
syndrom
develop
new
potenti
treatment
hamper
fact
object
criteria
avail
precis
assess
treatment
standard
tear
proteom
pattern
healthi
individu
may
serv
refer
measur
success
treatment
tear
proteom
profil
also
gener
use
inform
understand
interact
eye
contact
object
contact
len
len
implant
import
design
improv
eyecar
devic
maintain
health
eye
tf
analysi
may
challeng
small
volum
tf
collect
clinic
laboratori
normal
oper
condit
diseas
patient
minimum
tear
product
salin
flush
method
use
collect
eye
flush
fluid
content
tf
concentr
ultracentrifug
subsequ
proteom
analysi
comprehens
catalog
tf
protein
realiz
use
lcesimsm
lcmaldimsm
total
protein
identifi
less
tf
identifi
lcmaldimsm
alon
consumpt
tf
truncat
form
tf
lacrim
prp
cterminu
peptid
fragment
also
character
use
sec
malditofm
two
seldi
studi
demonstr
potenti
use
tear
proteom
pattern
noninvas
diagnost
detect
eye
diseas
dri
eye
syndrom
ss
multimark
model
establish
diseas
detect
superior
specif
sensit
identif
biomark
reveal
increas
inflammatori
marker
patient
dri
eye
decreas
protein
may
protect
function
use
lcqtofm
differenti
express
protein
tf
sampl
chronic
blephar
control
subject
identifi
also
valid
nine
protein
serum
albumin
lacritin
lysozym
igkappa
chain
viii
prolactin
induc
protein
cystatinsa
iii
pyruv
kinas
unnam
protein
found
downregul
blephar
patient
provid
insight
pathogenesi
diseas
presenc
integr
af
fundament
normal
develop
human
fetu
pregnanc
product
rate
chang
throughout
pregnanc
mainli
relat
function
differ
fetal
placent
amniot
compart
monitor
proteom
content
af
use
evalu
prematur
ruptur
fetal
membran
prom
develop
biomark
earli
detect
amniot
infect
inflamm
analysi
identif
af
protein
perform
use
offgel
ieflcmsm
lcfticrm
offgel
ief
allow
fraction
recoveri
protein
without
need
carrier
ampholyt
buffer
repres
advantag
compar
classic
liquidief
fraction
coupl
offgel
ief
nanolcmsm
result
identif
total
protein
af
prom
occur
deliveri
complic
infect
preterm
birth
earli
diagnosi
mandatori
order
decreas
complic
identifi
potenti
af
marker
present
af
absent
matern
blood
earli
detect
prom
approach
use
compar
plasma
af
sampl
collect
women
term
two
basement
membranespecif
heparan
sulfat
proteoglycan
protein
perlecan
agrin
found
present
af
absent
plasma
sampl
pregnant
women
presenc
intraamniot
infect
iai
often
associ
preterm
birth
advers
neonat
sequela
earli
diagnosi
iai
howev
hinder
insensit
nonspecif
test
use
seldim
af
profil
put
marker
includ
human
neutrophil
protein
hnp
calgranulin
b
c
insulinlik
growth
factorbind
protein
found
potenti
use
diagnosi
iai
malditofm
function
magnet
bead
also
report
proteom
analysi
af
supernat
rapid
detect
fetal
aneuploidi
immedi
amniocentesi
common
featur
share
among
differ
bodi
fluid
proteom
bodi
fluid
contain
larg
number
protein
within
extrem
wide
dynam
rang
concentr
therefor
deplet
highabund
protein
often
desir
bodi
fluid
order
achiev
comprehens
proteom
analysi
structur
modif
eg
glycosyl
truncat
protein
common
human
bodi
fluid
ptm
may
associ
diseas
state
therefor
need
character
quantifi
use
appropri
proteom
platform
minimum
overlap
protein
identifi
differ
bodi
fluid
suggest
proteom
content
bodi
fluid
distinct
also
impli
analyt
method
need
optim
specif
bodi
fluid
proteom
univers
proteom
platform
bodi
fluid
total
protein
concentr
bodi
fluid
vari
much
serum
highest
naf
lowest
abund
protein
also
differ
one
fluid
anoth
saliva
amylas
prp
ig
target
immunodeplet
wherea
serum
albumin
ig
hg
deplet
human
plasmaserum
repres
extens
studi
bodi
fluid
hbfp
analysi
insight
gain
plasmaserum
proteom
studi
help
advanc
analysi
fluid
proteom
compar
blood
bodi
fluid
may
express
sensit
specif
marker
certain
local
diseas
exampl
saliva
contain
mani
local
produc
protein
distinct
serum
protein
may
better
indic
oral
caviti
diseas
mani
studi
also
indic
bodi
fluid
eg
saliva
urin
sf
contain
number
serum
protein
could
indic
blood
contamin
serum
protein
highli
abund
transferrin
may
serv
surrog
marker
quantif
blood
contamin
bodi
fluid
hbfp
analysi
undoubtedli
longlast
approach
search
clinic
relev
diseas
biomark
tremend
effort
devot
largescal
identif
quantif
proteinspeptid
human
bodi
fluid
especi
plasmaserum
varieti
technolog
platform
includ
ms
electrophoresi
chromatographi
protein
array
evalu
hbfp
analysi
multiplex
proteom
platform
often
requir
order
achiev
comprehens
analysi
identif
protein
present
human
bodi
fluid
shotgun
proteom
studi
databas
search
may
produc
signific
number
incorrect
peptid
assign
process
valid
peptid
assign
often
reli
timeconsum
manual
verif
simpli
practic
analysi
larg
lcmsm
dataset
sever
statist
model
includ
probabilitybas
one
introduc
autom
valid
peptid
assign
msm
spectra
made
databas
search
tool
use
probabl
confid
measur
accompani
peptid
identif
allow
high
power
discrimin
correct
incorrect
protein
identif
estim
falseposit
error
rate
result
data
filter
therefor
provid
consist
object
standard
analyz
publish
largescal
protein
identif
dataset
develop
standard
method
sampl
collect
prepar
handl
import
hbfp
analysi
requir
collabor
effort
commun
work
specif
bodi
fluid
certifi
refer
materi
may
develop
sampl
qualiti
control
qualiti
assur
immunoaffin
deplet
appear
effect
mean
unmask
low
abund
protein
bodi
fluid
howev
concern
use
immunoaffin
deplet
may
remov
associ
protein
eg
cytokin
well
whether
immunodeplet
appropri
test
measur
chang
level
model
biomark
protein
diseas
normal
subject
quantit
ms
analysi
base
mrm
design
verifi
biomark
protein
show
consist
alter
diseas
normal
deplet
analysi
character
bodi
fluid
proteom
crucial
step
gear
toward
subsequ
biomark
discoveri
process
know
protein
concentr
ptm
state
dynam
rang
illustr
best
design
quantit
ms
approach
proteom
profil
studi
variabl
affect
product
protein
content
bodi
fluid
introduc
welladministr
proteom
sampl
analysi
import
point
robust
stabil
normal
bodi
fluid
proteom
rare
assess
know
complex
protein
pattern
constantli
chang
result
minor
physiolog
event
person
extrem
stabl
even
face
major
biolog
event
therefor
wellcharacter
bodi
fluid
proteom
like
enhanc
diseas
biomark
discoveri
process
although
larg
number
candid
bodi
fluid
found
liter
major
human
diseas
common
among
differ
type
diseas
question
rais
regard
sampl
prepar
handl
reproduc
accuraci
proteom
technolog
biomark
valid
clinic
util
test
specif
abund
biomark
protein
etc
factor
need
care
consid
prior
plan
proteom
biomark
studi
order
develop
robust
protein
marker
bodi
fluid
gener
step
procedur
follow
analysi
character
bodi
fluid
proteom
ii
differenti
proteom
profil
data
analysi
normal
statist
analysi
priorit
identifi
marker
iii
valid
new
independ
sampl
cohort
iv
establish
predict
model
v
clinic
util
test
step
reason
sampl
size
patient
group
match
control
warrant
comprehens
quantit
profil
bodi
fluid
key
statist
indispens
data
analysi
model
build
reliabl
data
also
highli
depend
proper
normal
data
aggress
valid
larg
sampl
cohort
technolog
improv
signific
impact
biomark
discoveri
studi
use
proteom
unlik
genom
profil
microarray
current
proteom
analysi
far
comprehens
evidenc
deepest
portion
hbfp
probe
msbase
proteom
meanwhil
major
current
proteom
technolog
rapid
highthroughput
microarray
profil
order
meet
requir
profil
larg
number
clinic
specimen
critic
advanc
proteom
technolog
toward
significantli
higher
level
comprehens
throughput
speed
accuraci
quantit
proteom
profil
key
unveil
differenti
express
protein
associ
diseas
isotop
taggingmsm
lcm
labelfre
format
repres
two
promis
method
quantit
ms
profil
bodi
fluid
immunoassay
still
extens
use
marker
valid
follow
proteom
discoveri
howev
assay
requir
specif
antibodi
antigen
protein
interest
therefor
alway
avail
quantit
lcmrm
ms
use
synthet
isotopelabel
peptid
intern
standard
well
demonstr
protein
quantif
method
may
prove
power
approach
valid
biomark
concern
put
biomark
identifi
proteom
approach
low
abund
protein
howev
hard
defin
whether
diseas
marker
low
highli
abund
perhap
high
prioriti
place
search
cancer
biomark
high
specif
share
proteom
biomark
among
multipl
type
cancer
surpris
consid
publish
studi
late
stage
cancer
healthi
control
human
cancer
epitheli
origin
may
share
similar
molecular
featur
late
stage
howev
precanc
earlystag
cancer
often
local
distinct
therefor
may
expect
specif
cancer
biomark
proteom
effort
shift
studi
precanc
earlystag
cancer
discov
biomark
truli
meaning
earli
detect
human
cancer
biomark
discoveri
studi
also
requir
robust
statist
strategi
sampl
size
calcul
data
analysi
predict
model
build
sampl
size
publish
clinic
proteom
studi
tend
small
presum
proteom
platform
use
capabl
handl
larg
number
sampl
howev
mean
sampl
size
compromis
determin
sampl
size
import
issu
sampl
small
size
may
lead
inaccur
result
mani
case
statist
tool
use
estim
minimum
sampl
size
need
base
random
variat
protein
among
proteom
sampl
desir
trueposit
rate
falseneg
rate
major
difficulti
confront
statist
predict
model
build
natur
multifactori
etiolog
heterogen
pathogen
pathway
mani
human
diseas
cancer
systemat
diseas
multimark
predict
model
often
built
order
enhanc
predict
power
despit
challeng
bodi
fluid
proteom
still
one
promis
approach
diseas
biomark
studi
clinic
proteom
commun
expect
accept
guidelin
protocol
set
diseas
diagnosi
especi
cancer
diagnosi
commun
guidelin
use
ration
standard
process
proteom
biomark
develop
enthusiast
new
breakthrough
near
futur
fast
develop
novel
ms
proteom
technolog
new
insight
unveil
hbfp
analysi
improv
patient
care
public
health
better
assess
diseas
suscept
prevent
diseas
monitor
treatment
respons
tabl
analysi
identif
protein
hbfp
use
msbase
proteom
put
biomark
human
cancer
discov
serum
proteom
analysi
cancer
type
candid
marker
proteom
platform
